Table 2. The mRNA levels of IL-1β, IL-6, IL-8 and IL-17 in FLS among six groups.
| Group | IL-1β | IL-6 | IL-8 | IL-17 |
|---|---|---|---|---|
| Control | 0.99 ± 0.01 | 0.98 ± 0.02 | 0.96 ± 0.04 | 0.97 ± 0.05 |
| miR-146a mimic | 0.38 ± 0.04* | 0.32 ± 0.03* | 0.36 ± 0.05* | 0.35 ± 0.06* |
| miR-146a inhibitor | 1.54 ± 0.09* | 1.41 ± 0.08* | 1.65 ± 0.14* | 1.78 ± 0.17* |
| Tak-242 | 0.36 ± 0.05* | 0.31 ± 0.02* | 0.33 ± 0.04* | 0.34 ± 0.07* |
| mimic + LPS TLR4 |
0.97 ± 0.03 1.86 ± 0.07*# |
0.96 ± 0.03 1.74 ± 0.09*# |
0.97 ± 0.02 1.98 ± 0.11*# |
0.98 ± 0.07 2.09 ± 0.11*# |
Note: *P < 0.05 compared with the control group; #P < 0.05 compared with the miR-146a inhibitor group; miR-146a: microRNA-146a; IL: interleukin. The experiment was repeated for three times. Each group had four wells from different patients every time, and cell samples form 12 patients were used in the experiments.